Christopher T Clark

This inventor holds 22 USPTO granted patents and 14 published patent applications, plus 3 CIPO patents and 16 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Gilead Sciences, Inc., Array Biopharma Inc., Microsoft Technology Licensing, LLC. Active years: 2011-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher T Clark. Retrieved from https://idiyas.com/inventor/christopher-t-clark

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 22 (Patent Applications = 14)

% Patents Active = 72.7

CIPO Patents = 3

EPO Patents = 16 (Patent Applications = 12)

Average Co-Inventor Count = 11.7

ph-index = 7

Forward Citations = 105(Granted Patents)

Location History:

Westminster, CO (US) (2011)
Boulder, CO (US) (2014)
Denver, CO (US) (2013 - 2017)
Seattle, WA (US) (2015 - 2024)

Company Filing History:

12 out of 946

Gilead Sciences, Inc.

Microsoft Technology Licensing, LLC

patents

4. 1 out of 2

The Allen Institute for Artificial Intelligence

patents

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

KHK Inhibitors

Quinoline Derivatives

Cot Modulators

Alpha 4 Beta 7 Integrin

Imidazopyridine Derivatives

P38 Inhibitors

6-Substituted Phenoxychroman

7-Phenoxychroman Carboxylic Acid

NLP Related Tasks

Contextualized Word Representations

Extensible System Action

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410160 - KHK inhibitors (2025-09-09),

2. 12053462 - Quinoline derivatives (2024-08-06),

3. 11905299 - Cot modulators and methods of use thereof (2024-02-20),

4. 11578069 - Compounds for inhibition of α4 β7 integrin (2023-02-14),

5. 11224600 - Compounds for inhibition of alpha 4 beta 7 integrin (2022-01-18),

6. 11179383 - Compounds for inhibition of α4β7 integrin (2021-11-23),

7. 11174256 - Imidazopyridine derivatives (2021-11-16),

8. 11116760 - Quinoline derivatives (2021-09-14),

9. 11066414 - Cot modulators and methods of use thereof (2021-07-20),

10. 11030414 - System and methods for performing NLP related tasks using contextualized word representations (2021-06-08),

11. 10642669 - Extensible system action for sharing while remaining in context (2020-05-05),

12. 10316017 - COT modulators and methods of use thereof (2019-06-11),

13. 10073722 - Extensible system action for sharing while remaining in context (2018-09-11),

14. 9878995 - Cot modulators and methods of use thereof (2018-01-30),

15. 9815818 - Cot modulators and methods of use thereof (2017-11-14),

Title: The Innovative Journey of Inventor Christopher T Clark

Introduction:

Christopher T Clark, a prolific inventor based in Seattle, WA (US), has made significant contributions to the field of pharmaceuticals with a total of 15 patents under his belt.

Latest Patents:

Among his latest patents is the groundbreaking work on Quinoline derivatives, focusing on compounds with therapeutic potential for treating inflammatory diseases. Additionally, he has made strides in developing Cot modulators for cancer treatment, showcasing his versatility in the medical field.

Career Highlights:

Clark's impressive career includes stints at renowned companies such as Gilead Sciences, Inc. and Microsoft Technology Licensing, LLC. At these organizations, he honed his expertise and spearheaded innovative projects in healthcare and technology sectors.

Collaborations:

Throughout his career, Clark has collaborated with esteemed professionals in the industry, including Kirk L Stevens and Taryn Campbell. These collaborations have led to the successful development and implementation of pioneering solutions in their respective fields.

Conclusion:

Inventor Christopher T Clark stands as a beacon of innovation, pushing boundaries and reshaping industries with his groundbreaking patents and collaborative efforts. His relentless pursuit of excellence continues to inspire future generations of inventors and innovators worldwide.

Profile summary based on public USPTO records.